Effect of evolocumab or ezetimibe added to moderateor high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia the LAPLACE-2 randomized clinical trial

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F14%3A00059164" target="_blank" >RIV/00023001:_____/14:00059164 - isvavai.cz</a>

Výsledek na webu

<a href="http://jama.jamanetwork.com/article.aspx?articleid=1869210" target="_blank" >http://jama.jamanetwork.com/article.aspx?articleid=1869210</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1001/jama.2014.4030" target="_blank" >10.1001/jama.2014.4030</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Effect of evolocumab or ezetimibe added to moderateor high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia the LAPLACE-2 randomized clinical trial

Popis výsledku v původním jazyce

IMPORTANCE In phase 2 studies, evolocumab, a fully human monoclonal antibody to PCSK9, reduced LDL-C levels in patients receiving statin therapy. OBJECTIVE To evaluate the efficacy and tolerability of evolocumab when used in combination with a moderate-vs high-intensity statin. CONCLUSIONS AND RELEVANCE In this 12-week trial conducted among patients with primary hypercholesterolemia and mixed dyslipidemia, evolocumab added to moderate-or high-intensity statin therapy resulted in additional LDL-C lowering. Further studies are needed to evaluate the longer-term clinical outcomes and safety of this approach for LDL-C lowering. DESIGN, SETTING, AND PATIENTS Phase 3, 12-week, randomized, double-blind, placebo-and ezetimibe-controlled study conducted betweenJanuary and December of 2013 in patients with primary hypercholesterolemia and mixed dyslipidemia at 198 sites in 17 countries

Název v anglickém jazyce

Effect of evolocumab or ezetimibe added to moderateor high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia the LAPLACE-2 randomized clinical trial

Popis výsledku anglicky

IMPORTANCE In phase 2 studies, evolocumab, a fully human monoclonal antibody to PCSK9, reduced LDL-C levels in patients receiving statin therapy. OBJECTIVE To evaluate the efficacy and tolerability of evolocumab when used in combination with a moderate-vs high-intensity statin. CONCLUSIONS AND RELEVANCE In this 12-week trial conducted among patients with primary hypercholesterolemia and mixed dyslipidemia, evolocumab added to moderate-or high-intensity statin therapy resulted in additional LDL-C lowering. Further studies are needed to evaluate the longer-term clinical outcomes and safety of this approach for LDL-C lowering. DESIGN, SETTING, AND PATIENTS Phase 3, 12-week, randomized, double-blind, placebo-and ezetimibe-controlled study conducted betweenJanuary and December of 2013 in patients with primary hypercholesterolemia and mixed dyslipidemia at 198 sites in 17 countries

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

JAMA

ISSN

0098-7484

e-ISSN

—

Svazek periodika

311

Číslo periodika v rámci svazku

18

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

13

Strana od-do

1870-1882

Kód UT WoS článku

000335798100019

EID výsledku v databázi Scopus

—